The US Food and Drug Administration has approved Merck’s oral PCSK9 inhibitor, the first pill in a drug class that has been available only as an injection since its introduction in 2015. The approval, announced July 16, marks a significant shift in how a key cholesterol-lowering therapy can be delivered and prescribed.
PCSK9 inhibitors work by blocking the protein PCSK9 (proprotein convertase subtilisin/kexin type 9), which normally degrades LDL cholesterol receptors on liver cells. By inhibiting PCSK9, the drugs increase the number of receptors available to clear LDL (“bad”) cholesterol from the bloodstream, producing dramatic reductions, often by 50% to 60% or more, when added to statin therapy.
The first two PCSK9 inhibitors to reach the market, Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab), were monoclonal antibodies requiring subcutaneous injection every two to four weeks. Both drugs were approved in 2015 and have accumulated extensive long-term safety data, including the FOURIER and ODYSSEY OUTCOMES trials demonstrating cardiovascular event reduction. A third injectable PCSK9, Novartis’s inclisiran, uses a different mechanism (small interfering RNA) and requires only twice-yearly dosing after an initial loading schedule.
The arrival of an oral option could expand the addressable patient population significantly. Injectable PCSK9s, despite their efficacy, have been limited by insurance hurdles, patient reluctance toward self-injection, and a relatively narrow prescribing base dominated by specialists. An oral formulation can be prescribed by primary care physicians and integrated into standard daily medication regimens without injection training or refrigeration requirements.
Merck has not yet disclosed the drug’s generic name, exact LDL reduction data from its pivotal trials, or the list price. Pricing will be a critical factor in adoption. Repatha and Praluent faced significant payer pushback at their original launch prices above $14,000 annually, though list prices have since been reduced through discounts and competition.
The approval follows years of efforts across the industry to develop an oral PCSK9. Pfizer, Novartis, and other companies have pursued oral candidates with varying degrees of success. Merck’s achievement of an oral formulation, overcoming the challenge of delivering a large molecule or a small-molecule mimetic with sufficient oral bioavailability, positions it for a dominant share of the PCSK9 market, provided pricing and payer coverage align.
The broader lipid-lowering landscape continues to evolve rapidly. In addition to oral PCSK9s, the field is seeing progress in Lp(a)-targeting therapies, CETP inhibitors, and bempedoic acid combinations. The oral PCSK9 approval adds a new tool that could help close the treatment gap: an estimated 30% to 40% of patients who qualify for PCSK9 therapy under current guidelines are not receiving it, many because of the injectable requirement.
Sources
Keshavan M. “FDA approves Merck’s oral PCSK9 drug, a first.” STAT News, July 16, 2026. https://www.statnews.com/2026/07/16/biotech-news-fda-approves-merck-oral-pcsk9-drug-in-a-first/